Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 7, 2015Achillion announces the nomination of its first orally bioavailable, highly potent and specific factor D inhibitor, ACH-4471, which is expected to enter clinical development during the first quarter of 2016.
More »
Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL), a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System (CNS)
December 6, 2015Atara and collaborating investigators at Memorial Sloan Kettering are reporting overall response rate >70% and no GvHD observed in patients with refractory CMV chorioretinitis or meningoencephalitis.
More »
Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium
December 3, 2015Preclinical and clinical data posters will be presented that support clinical strategy for entinostat and potential use in immuno-oncology combination therapies.
More »